Document:

Exhibit
10.17

 

 

 

PENAO
Resolution

Milestone
Payments

 

It
is hereby resolved with immediate effect the Board of Directors of PENAO Pty Ltd (the Company) (ACN 634 333 387) approve a delay to the
estimated delivery dates of the milestone payments Beroni must pay the Company.

 

The
rationale for the delay is that Beroni has just submitted its prospectus to list on the NASDAQ where it expects to raise significant
funds. The process is estimated to complete by August 2021 and payment will be made then, if not before.

 

From
an operational perspective, it would be prudent to delay initiation of manufacture until we have certainty of China’s NMPA standards.
A Request for Proposal prioritising NMPA engagement asks CRO for costed tenders to write to the NMPA and arrange a pre-IND meeting. Questions
will include NMPA expectations regarding Drug Substance purity, tech transfer and equipment standards.

 

Contemporary
Milestone Payments:

 

	 	●	$1.3M
    targeted for 01st March 2021. This is milestone payment Initiation of drug manufacturing campaign with an approved
    contract manufacturing organisation.
	 	●	$1.5M
    targeted for 01st June 2021. This is milestone payment China NMPA engagement.

 

In
accordance with the PENAO Shareholders Variation Agreement “In order to reimburse the Company for costs incurred in achieving
the milestones, and to support the Company’s activities and contribute to the operating capital, Beroni must pay the Company the
following amounts within 7 Business Days after the achievement of each of the below milestones and the Company must issue the Shares,
as follows:

 

    	 

    	 

    

 

	 	 	Version 21 Dec 2020	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	Shares to be issued	 	 	 	 	 	 	 	Notes to be issued	 
	#	 	Milestone	 	Estimated date	 	 	Amount to be paid by Beroni	 	 	 	Beroni	 	 	 	NSi - Shares	 	 	 	Total Shares to be issued	 	 	 	NSi - Notes	 	 	 	NSi Shares + Notes	 
	0	 	Provided under term sheet with Cystemix	 	received	 	$	400,000	 	 	 	40,000	 	 	 	60,000	 	 	 	100,000	 	 	 	0	 	 	 	60,000	 
	 	 	Progress payments to PENAO	 	March, June, August 2020	 	$	350,000	 	 	 	35,000	 	 	 	0	 	 	 	35,000	 	 	 	52,500	 	 	 	52,500	 
	1	 	Revision to Shareholders Agreement and enter Convertible Notes Agreement	 	31-Dec-20	 	$	300,000	 	 	 	30,000	 	 	 	9,000	 	 	 	39,000	 	 	 	36,000	 	 	 	45,000	 
	2	 	Initiation of drug manufacturing campaign with an approved contract manufacturing organisation	 	1-Mar-21	 	$	1,300,000	 	 	 	130,000	 	 	 	83,115	 	 	 	213,115	 	 	 	111,885	 	 	 	195,000	 
	3	 	China NMPA engagement	 	1-Jun-21	 	$	1,500,000	 	 	 	150,000	 	 	 	95,902	 	 	 	245,902	 	 	 	129,098	 	 	 	225,000	 
	4	 	Progress payment	 	1-Sep-21	 	$	1,000,000	 	 	 	100,000	 	 	 	63,934	 	 	 	163,934	 	 	 	86,066	 	 	 	150,000	 
	5	 	Contract Research Organisation engagement	 	1-Dec-21	 	$	1,000,000	 	 	 	100,000	 	 	 	63,934	 	 	 	163,934	 	 	 	86,066	 	 	 	150,000	 
	6	 	 Clinical Study Site Initiation	 	1-Mar-22	 	$	1,000,000	 	 	 	100,000	 	 	 	63,934	 	 	 	163,934	 	 	 	86,066	 	 	 	150,000	 
	 7a	 	Progress payment	 	1-Jun-22	 	$	1,000,000	 	 	 	100,000	 	 	 	63,934	 	 	 	163,934	 	 	 	86,066	 	 	 	150,000	 
	 7b	 	Progress payment	 	1-Sep-22	 	$	1,000,000	 	 	 	100,000	 	 	 	63,934	 	 	 	163,934	 	 	 	86,066	 	 	 	150,000	 
	7c	 	Progress payment	 	1-Dec-22	 	$	1,000,000	 	 	 	100,000	 	 	 	63,934	 	 	 	163,934	 	 	 	86,066	 	 	 	150,000	 
	 	 	TOTAL	 	 	 	$	9,850,000	 	 	 	985,000	 	 	 	631,621	 	 	 	1,616,621	 	 	 	845,879	 	 	 	1,477,500	 
	 	 	Proportion of shareholding	 	 	 	 	 	 	 	 	60.93	%	 	 	39.07	%	 	 	 	 	 	 	 	 	 	 	 	 

 

    	 

    	 

    

 

This
resolution was passed by a simple majority in a circular communication to the Board of Directors by Vincent Ruffles on the 21st
April 2021.

 

	Signed	 	 	Date	27/4/2021
	 	Peter
    French, ChairExhibit
10.18

 

ThorGene
(Beijing) Medical Technology Co., Ltd.

 

 

 

 

 

 

 

Genetic
Testing Service Agreement

 

 

 

ThorGene
(Beijing) Medical Technology Co., Ltd.

 

 

 

 

 

 

 

    	Address: Biopharmaceutical Park, Technology Innovation Six Street, Economic and Technological Development Zone of Yizhuang, Beijing Tel: 010-56315456

    	
 ThorGene (Beijing) Medical Technology Co., Ltd.

    

 

Genetic
Testing Service Agreement

 

Party
A: Tianjin Beroni Biotechnology Co., Ltd.

 

Address:
10F, Intelligent Building, Zhonglian Industrial Park, Zhong Bei Town, Xi Qing District, Tianjin, China

 

Tel:
022-58530396

 

Contact:
Jiaxing Zhu

 

 

Party
B: ThorGene (Beijing) Medical Technology Co., Ltd.

 

Address:
A1-2F, Biopharmaceutical Park, No. 88, Technology Innovation Six Street, Economic and Technological Development Zone, Beijing

 

Tel:
010-56315456

 

Contact:
Guanglei Liu

 

 

In
accordance with relevant laws and regulations of People’s Republic of China, two parties have reached the following agreement on
health management services with principles of equality, voluntariness and mutual benefit.

 

I.
Cooperation Scope

 

Party
A entrusts Party B to provide genetic testing services by carrying out gene test and issuing test results.

 

    	Address: Biopharmaceutical Park, Technology Innovation Six Street, Economic and Technological Development Zone of Yizhuang, Beijing Tel: 010-56315456

    	
 ThorGene (Beijing) Medical Technology Co., Ltd.

    

 

II.
Responsibilities of Party A

 

2.1
Party A is responsible for quality control before specimens are sent to Party B. Specimens provided to Party B shall conform to collection
requirements, including preparation of patients, sampling and storage of specimens. (See Annex 1 for details.)

 

2.2
If specimens are lost or damaged in delivery due to default of express company, Party A shall negotiate with express company to claim
and Party B shall provide assistance when needed.

 

2.3
An objection to test report shall be submitted to Party B within three months of the remaining specimens’ shelf life. If no objection
is raised during that period, Party A will be deemed to have fully accepted the test results.

 

2.4
Party A shall not manufacture, sell, act as an agent or promote the identical products with Party B’s products in any other ways
inside or outside Party A’s distribution territory.

 

2.5
Party A shall be obliged to protect business secret disclosed by Party B no matter in negotiation, validity period or after termination
of the Agreement.

 

III.
Responsibilities of Party B

 

3.1
Party B, as a partner and provider in health services of Party A, shall provide “genetic testing services” to Party A in
accordance with this Agreement.

 

3.2
Party B shall provide early-stage product training for Party A’s sales personnel for one or two times, and training time may be
determined through negotiation between two parties. Corresponding electronic promotional materials and report templates of cooperative
products shall be provided to Party A by Party B.

 

3.3
Party B hereby promises to train Party A’s staff to sample, preprocess and preserve specimens, for them to operate test items,
and provide sampling requirements for special specimens.

 

    	Address: Biopharmaceutical Park, Technology Innovation Six Street, Economic and Technological Development Zone of Yizhuang, Beijing Tel: 010-56315456

    	
 ThorGene (Beijing) Medical Technology Co., Ltd.

    

 

3.4
Party B shall send reports at appointed time agreed by both parties and keep tested specimens and reports for three months after which
Party B shall not keep the specimens and reports if Party A does not require. Party B shall check the integrity and validity when receiving
the specimens, and have right to reject unqualified specimens. If test reports are found inaccurate due to Party B’s test error,
Party B shall bear relevant responsibilities and indemnify Party A for any loss caused thereby. If reporting time exceeds the time agreed
in Agreement, Party B shall compensate by 0.1% of specimen test price per day; if the delay is caused by unqualified specimens sent by
Party A, responsibility shall be borne by Party A. If Party A fails to give payment on time as agreed, it shall pay Party B a penalty
equal to 0.1% of payable amount per day for each day delayed.

 

3.5
Party B shall make sure accuracy of tests and keep relevant information provided by Party A confidential in accordance with requirements
of relevant national laws and regulations.

 

3.6
Any additional tests for clinical needs required by two parties shall be settled through friendly negotiation. For newly proposed test
items, Party B shall give Party A a reply within 5 working days.

 

3.7
Party B shall truthfully and professionally interpret all test reports to Party A.

 

3.8
Party B shall guarantee all relevant services will be performed in full accordance with standards agreed herein during whole term of
cooperation as stated in the Agreement.

 

    	Address: Biopharmaceutical Park, Technology Innovation Six Street, Economic and Technological Development Zone of Yizhuang, Beijing Tel: 010-56315456

    	
 ThorGene (Beijing) Medical Technology Co., Ltd.

    

 

IV.
Product Price & Period, Payment

 

4.1
Product Price & Period

 

List
of genetic health services products (The following quotation just includes blood specimens and electronic reports. The cost of consumables,
express and paper report of other specimens will be calculated separately.)

 

	Type	 	Product
    Name	 	Detailed
    Testing Items	 	Significance	 	Specimen
    Type	 	Report
    Time	 	Price/Yuan	 	Final
    Settlement Price	 	Report
    Printing Fee	 	Pages
    of Reports
	Single
    Gene Testing	 	P53
    Cancer Suppressor Gene Testing	Based	 	P53 Cancer Suppressor
    Gene Testing	 	The
    P53 gene is related to 50% of human tumors. Through testing and assessing the body’s tumor suppressor ability, it is more forward-looking
    and scientific to guide people to prevent tumors and reduce the risk of cancers.	 	Oral swab/blood	 	7 days	 	100	 	20	 	10	 	4
	 	Full	 	P53 Cancer Suppressor Gene
    Testing	 	 	Oral swab/blood	 	10 days	 	299	 	60	 	12	 	12
	 	Lung Cancer
    Susceptibility Gene Testing 	 	Lung Cancer Susceptibility
    Gene Testing	 	Through the testing of lung
    cancer susceptibility genes, we can discover hidden “cancer mines” in the body, assess the risk of lung cancer, provide
    advice on diet and exercise that may prevent lung cancer to change the external cause of lung cancer, and formulate disease prevention
    programs based on the test results to delay or prevent the occurrence of cancer.	 	Oral swab/blood	 	10 days	 	200	 	40	 	12	 	8
	 	Gastric Cancer
    Susceptibility Gene Testing	 	Gastric Cancer Susceptibility
    Gene Testing	 	Through testing the gastric
    cancer susceptibility genes, we can discover hidden “cancer landmines” in the body, assess the risk of gastric cancer,
    provide diet and exercise recommendations that may prevent gastric cancer to change the external cause of gastric cancer, and formulate
    disease prevention programs based on the test results to delay or prevent the occurrence of cancer.	 	Oral swab/blood	 	10 days	 	200	 	40	 	12	 	8
	 	Liver Cancer
    Susceptibility Gene Testing	 	Liver Cancer Susceptibility
    Gene Testing	 	Through the testing of liver
    cancer susceptibility genes, we can discover hidden “cancer mines” in the body, assess the risk of liver cancer, provide
    diet and exercise recommendations that may prevent liver cancer to change the external causes of liver cancer, and formulate disease
    prevention programs based on the test results to delay or prevent the occurrence of cancer.	 	Oral swab/blood	 	10 days	 	200	 	40	 	12	 	8

 

    	Address: Biopharmaceutical Park, Technology Innovation Six Street, Economic and Technological Development Zone of Yizhuang, Beijing Tel: 010-56315456

    	
 ThorGene (Beijing) Medical Technology Co., Ltd.

    

 

	 	 	Colorectal
    Cancer Susceptibility Gene Testing	 	Colorectal
    Cancer Susceptibility Gene Testing	 	Through
    testing the colorectal cancer susceptibility genes, we can discover hidden “cancer landmines” in the body, assess the
    risk of colorectal cancer, provide diet and exercise recommendations that may prevent colorectal cancer to change the external causes
    of colorectal cancer, and formulate disease prevention programs based on the test results to delay or prevent the occurrence of cancer.	 	Oral
    swab/blood	 	10
    days	 	200	 	40	 	12	 	8
	 	 	Prostate
    Cancer Susceptibility Gene Testing	 	Prostate
    Cancer Susceptibility Gene Testing	 	Through
    testing the prostate cancer susceptibility genes, we can discover hidden “cancer landmines” in the body, assess the risk
    of prostate cancer, provide diet and exercise recommendations that may prevent prostate cancer to change the external cause of prostate
    cancer, and formulate disease prevention programs based on the test results to delay or prevent the occurrence of cancer.	 	Oral
    swab/blood	 	10
    days	 	200	 	40	 	12	 	8
	 	 	Breast
    Cancer Susceptibility Gene Testing	 	Breast
    Cancer Susceptibility Gene Testing	 	Through
    the testing of breast cancer susceptibility genes, we can discover hidden “cancer mines” in the body, assess the risk
    of breast cancer, provide advice on diet and exercise that may prevent breast cancer to change the external cause of breast cancer,
    formulate disease prevention programs based on the test results to delay or prevent the occurrence of cancer.	 	Oral
    swab/blood	 	10
    days	 	200	 	40	 	12	 	8
	 	 	Cervical
    Cancer Susceptibility Gene Testing	 	Cervical
    Cancer Susceptibility Gene Testing	 	Through
    the testing of cervical cancer susceptibility genes, we can discover hidden “cancer mines” in the body, assess the risk
    of cervical cancer, provide recommendations on diet and exercise that may prevent cervical cancer to change the external cause of
    cervical cancer, formulate disease prevention programs based on the test results to delay or prevent the occurrence of cancer.	 	Oral
    swab/blood	 	10
    days	 	200	 	40	 	14	 	8

 

    	Address: Biopharmaceutical Park, Technology Innovation Six Street, Economic and Technological Development Zone of Yizhuang, Beijing Tel: 010-56315456

    	
 ThorGene (Beijing) Medical Technology Co., Ltd.

    

 

	 	 	Thyroid
    Cancer Susceptibility Gene Testing	 	Thyroid
    Cancer Susceptibility Gene Testing	 	Through
    the testing thyroid cancer susceptibility genes, we can discover hidden “cancer mines” in the body, assess the risk of
    thyroid cancer, provide diet and exercise recommendations that may prevent thyroid cancer to change the external cause of thyroid
    cancer, and formulate disease prevention programs based on the test results to delay or prevent the occurrence of cancer.	 	Oral
    swab/blood	 	10
    days	 	200	 	40	 	14	 	8
	 	 	Apolipoprotein E
    Gene Testing	 	Coronary
    heart disease, cerebral infarction, senile dementia	 	According
    to the early detection of APOE, we can improve the bad lifestyle in time, and reasonably carry out drug intervention, which can help
    prevent and diagnose coronary heart disease, cerebral infarction, and Alzheimer’s related diseases caused by abnormal APOE.	 	Oral
    swab/blood	 	10
    days	 	200	 	40	 	10	 	4
	 	 	Alcohol
    Metabolism	 	Ethanol
    metabolic capacity, acetaldehyde metabolism capacity	 	By
    analyzing the subject’s alcohol metabolism-related genes, it is possible to assess the strength of the individual’s ability
    to metabolize alcohol, so as to help the individual to know early, prevent early, and avoid the impact of unfavorable factors on
    health.	 	Oral
    swab/blood	 	10
    days	 	200	 	40	 	10	 	4
	 	 	Pancreatic
    Cancer Susceptibility Gene Testing	 	Pancreatic
    Cancer Susceptibility Gene Testing, 4 sites	 	Through
    the testing of pancreatic cancer susceptibility genes, we can discover hidden “cancer mines” in the body, assess the
    risk of pancreatic cancer, provide diet and exercise recommendations that may prevent pancreatic cancer to change the external cause
    of pancreatic cancer, and formulate disease prevention programs based on the test results to delay or prevent the occurrence of cancer.	 	Oral
    swab/blood	 	10
    days	 	399	 	80	 	14	 	10
	 	 	Parkinson’s
    Disease Susceptibility Gene Testing	 	Parkinson’s
    Disease Susceptibility Gene Testing	 	Through
    the testing of Parkinson’s disease susceptibility genes, assess the risk of Parkinson’s disease, provide diet and exercise
    recommendations that may prevent the Parkinson’s disease to change the external cause of Parkinson’s disease, formulate
    disease prevention programs based on the test results to delay or prevent the occurrence of cancer.	 	Oral
    swab/blood	 	10
    days	 	200	 	40	 	14	 	10

 

    	Address: Biopharmaceutical Park, Technology Innovation Six Street, Economic and Technological Development Zone of Yizhuang, Beijing Tel: 010-56315456

    	
 ThorGene (Beijing) Medical Technology Co., Ltd.

    

 

	 	 	Myocardial
    Infarction Susceptibility Gene Testing 	 	Myocardial
    Infarction Susceptibility Gene Testing	 	Through
    myocardial infarction susceptibility gene testing, we can assess the risk of myocardial infarction, provide diet and exercise recommendations
    that may prevent myocardial infarction to change the external cause of myocardial infarction, and formulate disease prevention programs
    based on the test results to delay or prevent the occurrence of cancer.	 	Oral
    swab/blood	 	10
    days	 	200	 	40	 	14	 	10
	 	 	Immunity
    Gene Testing	 	Basic
    immunity, antiviral ability, respiratory diseases	 	Differences
    in immunity are essentially genetic differences. Through the testing of immunity-related genes, innate immunity can be assessed,
    and one’s own immunity can be scientifically improved according to professional recommendations.	 	Oral
    swab/blood	 	10
    days	 	599	 	120	 	22	 	25
	 	 	Human
    Papilloma Virus (HPV) Gene Testing	 	HPV	 	HPV	 	Cast-off
    cells of cervical carcinoma	 	5
    days	 	350	 	75	 	10	 	1
	 	 	Early
    Screening for Colorectal Cancer - S9 Gene Testing	 	Septin9
    gene methylation	 	Early
    colorectal cancer usually has no obvious symptoms, and the cure rate of early colorectal cancer can reach 90%. By testing the methylated
    Septin9 genes, it is possible to preliminarily determine whether the subject is at risk of colorectal cancer. Through regular S9
    screening, colorectal cancer can be detected at an early stage for timely diagnosis and treatment.	 	Blood	 	5
    days	 	1980	 	400	 	14	 	7

 

    	Address: Biopharmaceutical Park, Technology Innovation Six Street, Economic and Technological Development Zone of Yizhuang, Beijing Tel: 010-56315456

    	
 ThorGene (Beijing) Medical Technology Co., Ltd.

    

 

	 	 	Gene
    Testing for Usage of Anti-hypertension Drugs	 	 

    Gene
    mutation of ADRB1,NPPA,CYP2C9*3 and ACE

     
	 	Through
    the testing of genes related to individualized drugs for hypertension, we can evaluate the efficacy and adverse reactions of individuals
    to different drugs, guide the medication and adjust the dosage of medications, reduce the harm of drugs to the human body, and improve
    the therapeutic effect at the same time.	 	Oral
    swab/blood	 	7
    days	 	588	 	150	 	14	 	5
	 	 	Gastrointestinal
    Cancer Susceptibility Gene Testing	 	Gastrointestinal
                                            Cancer Susceptibility Gene Testing, 8 sites

     
	 	Through
    the testing of gastrointestinal cancer susceptibility genes, we can discover hidden “cancer landmines” in the body, assess
    the risk of gastrointestinal cancer, provide diet and exercise recommendations that may prevent gastrointestinal cancer to change
    the external causes of gastrointestinal cancer, and formulate disease prevention programs based on the test results to delay or prevent
    the occurrence of cancer.	 	Oral
    swab/blood	 	10
    days	 	599	 	120	 	16	 	13
	 	 	Susceptibility
    Gene Testing of Pancreatic Cancer, Prostate Cancer and Thyroid Cancer, Male (3 items)	 	Gene
    testing of pancreatic cancer, prostate cancer and thyroid cancer	 	Through
    the susceptibility gene testing of pancreatic cancer, prostate cancer and thyroid cancer of the male, we can discover hidden “cancer
    mines” in the body, assess the risk of diseases, provide diet and exercise recommendations to change external factors, and
    formulate disease prevention programs based on the test results to delay or prevent the occurrence of cancer.	 	Oral
    swab/blood	 	10
    days	 	799	 	160	 	18	 	16
	 	 	Susceptibility
    Gene Testing of Pancreatic Cancer, Breast Cancer and Thyroid Cancer, Female  	 	Gene
    testing of pancreatic cancer, breast cancer and thyroid cancer	 	Through
    the susceptibility gene testing of pancreatic cancer, breast cancer and thyroid cancer of the female, we can find hidden “cancer
    mines” in the body, assess the risk of diseases, provide diet and exercise recommendations to change external causes, and formulate
    disease prevention programs based on the test results to delay or prevent The occurrence of cancer.	 	Oral
    swab/blood	 	10
    days	 	799	 	160	 	18	 	16

 

    	Address: Biopharmaceutical Park, Technology Innovation Six Street, Economic and Technological Development Zone of Yizhuang, Beijing Tel: 010-56315456

    	
 ThorGene (Beijing) Medical Technology Co., Ltd.

    

 

	Disease
                                            Risk Screening Package

     
	 	Common
    Tumor Susceptibility Gene Testing	 	Male
                                            10/Female 13

    Esophageal
    cancer, lung cancer, nasopharyngeal cancer, gastric cancer, liver cancer, colorectal cancer, thyroid cancer, bladder cancer, lymphoma,
    prostate cancer (male), breast cancer (female), cervical cancer (female), ovarian cancer (female), uterus endometrial cancer (female)
	 	Through
    male tumor susceptibility gene testing, we can discover hidden “cancer mines” in the body, assess the risk of 10 tumors,
    provide advice on diet and exercise to change the external causes of tumors, formulate disease prevention programs based on the test
    results to delay or prevent the occurrence of cancer./ Through female tumor susceptibility gene testing, we can discover hidden “cancer
    mines” in the body, assess the risk of 13 tumors, provide advice on diet and exercise to change the external causes of tumors,
    formulate disease prevention programs based on the test results to delay or prevent the occurrence of cancer.	 	Oral
    swab/blood	 	10
    days	 	500	 	100	 	33	 	45
	 	 	Common
    Cardiovascular and Cerebrovascular Diseases Susceptibility Gene Testing	 	13
                                            items

    Hypertension,
    coronary heart disease, chronic obstructive pulmonary disease, atrial fibrillation, primary biliary cirrhosis, myocardial infarction,
    hypertriglyceridemia, hyperuricemia, dilated cardiomyopathy, Parkinson’s syndrome, Alzheimer’s disease, type 1 diabetes,
    type 2 diabetes.
	 	Hypertension,
    coronary heart disease, chronic obstructive pulmonary disease, atrial fibrillation, primary biliary cirrhosis, myocardial infarction,
    hypertriglyceridemia, hyperuricemia, dilated cardiomyopathy, Parkinson’s syndrome, Alzheimer’s disease, type 1 diabetes,
    type 2 diabetes.	 	Oral
    swab/blood	 	10
    days	 	500	 	100	 	33	 	45
	 	 	Tumor
    Susceptibility Gene Testing	 	Male
                                            20/Female 23

    Nasopharyngeal
    cancer, lung cancer, liver cancer, melanoma, laryngeal cancer, basal cell carcinoma, acute lymphocytic leukemia, thyroid cancer,
    colorectal cancer, oral cancer, lymphoma, chronic lymphocytic leukemia, carcinoma gallbladder, bladder cancer, glioma, kidney cancer,
    esophageal cancer, stomach cancer, pancreatic cancer, prostate cancer (male), endometrial cancer (female), cervical cancer (female),
    breast cancer (female), ovarian cancer (female)
	 	Through
    male tumor susceptibility gene testing, we can discover hidden “cancer mines” in the body, assess the risk of 20 tumors,
    provide advice on diet and exercise to change the external causes of tumors, formulate disease prevention programs based on the test
    results to delay or prevent the occurrence of cancer./ Through female tumor susceptibility gene testing, we can discover hidden “cancer
    mines” in the body, assess the risk of 23 tumors, provide advice on diet and exercise to change the external causes of tumors,
    formulate disease prevention programs based on the test results to delay or prevent the occurrence of cancer.	 	Oral
    swab/blood	 	10
    days	 	800	 	160	 	55	 	90

 

    	Address: Biopharmaceutical Park, Technology Innovation Six Street, Economic and Technological Development Zone of Yizhuang, Beijing Tel: 010-56315456

    	
 ThorGene (Beijing) Medical Technology Co., Ltd.

    

 

	 	 	Cardiovascular
    and Cerebrovascular Diseases Susceptibility Gene Testing	 	27
                                            items

    Hypertension,
    coronary heart disease, chronic obstructive pulmonary disease, primary biliary cirrhosis, myocardial infarction, atrial fibrillation,
    rheumatoid arthritis, dilated cardiomyopathy, phlebothrombosis, epilepsy, amyotrophic lateral sclerosis, sudden cardiac death

    ,
    nephrotic syndrome, hyperuricemia, hyperthyroidism, type 1 diabetes, type 2 diabetes, hypertriglyceridemia, obesity, osteoporosis,
    Parkinson’s syndrome, Alzheimer’s disease, autoimmune thyroid disease, manic-depressive psychosis, major depressive disorder,
    Crohn’s disease, chronic bronchitis.

     
	 	Cardiovascular
    and cerebrovascular disease susceptibility gene testing can indicate 27 risk of cardiovascular and cerebrovascular diseases, help
    provide diet and exercise recommendations that prevent cardiovascular and cerebrovascular diseases to change the external causes
    of cardiovascular and cerebrovascular diseases, and formulate disease prevention programs based on the test results to delay or prevent
    the occurrence of diseases.	 	Oral
    swab/blood	 	10
    days	 	800	 	160	 	55	 	90
	 	 	Genetic
    Testing for Comprehensive Genetic Risk 	 	Male
                                            64/Female 68

    Breast
    cancer (female), prostate cancer (male), ovarian cancer (female), oral cancer, laryngeal cancer, basal cell carcinoma, endometrial
    cancer (female), uterine fibroids (female), cervical cancer (female), acute lymphocytic leukemia, chronic lymphocytic leukemia, thyroid
    cancer, glioma, colorectal cancer, liver cancer, lung cancer, kidney cancer, gastric cancer, gallbladder carcinoma, pancreatic cancer,
    bladder cancer, esophageal cancer, melanoma, nasopharyngeal cancer, lymphoma, atrial fibrillation, phlebothrombosis, sudden cardiac
    death, myocardial infarction, coronary heart disease, hypertension, dilated cardiomyopathy, obesity, type 1 diabetes, type 2 diabetes,
    hypertriglyceridemia, hyperthyroidism, polycystic ovary syndrome(female), benign prostatic hyperplasia (male), osteoporosis, hyperuricemia,
    autoimmune thyroid disease, vitiligo, allergic rhinitis, psoriasis, ankylosing spondylitis, systemic lupus erythematosus, primary
    biliary cirrhosis, rheumatoid arthritis, chronic kidney disease, nephrotic syndrome, epilepsy, manic-depressive psychosis, major
    depressive disorder, schizophrenia, alcohol dependence, Parkinson’s syndrome, Alzheimer’s disease, amyotrophic lateral
    sclerosis, ulcerative colitis, gallstones, hepatitis B, duodenal ulcer, Crohn’s disease, glaucoma, age-related macular degeneration,
    pathological myopia, chronic bronchitis, chronic obstructive pulmonary disease, asthma.

     
	 	Breast
    cancer (female), prostate cancer (male), ovarian cancer (female), oral cancer, laryngeal cancer, basal cell carcinoma, endometrial
    cancer (female), uterine fibroids (female), cervical cancer (female), acute lymphocytic leukemia, chronic lymphocytic leukemia, thyroid
    cancer, glioma, colorectal cancer, liver cancer, lung cancer, kidney cancer, gastric cancer, gallbladder carcinoma, pancreatic cancer,
    bladder cancer, esophageal cancer, melanoma, nasopharyngeal cancer, lymphoma, atrial fibrillation, phlebothrombosis, sudden cardiac
    death, myocardial infarction, coronary heart disease, hypertension, dilated cardiomyopathy, obesity, type 1 diabetes, type 2 diabetes,
    hypertriglyceridemia, hyperthyroidism, polycystic ovary syndrome(female), benign prostatic hyperplasia (male), osteoporosis, hyperuricemia,
    autoimmune thyroid disease, vitiligo, allergic rhinitis, psoriasis, ankylosing spondylitis, systemic lupus erythematosus, primary
    biliary cirrhosis, rheumatoid arthritis, chronic kidney disease, nephrotic syndrome, epilepsy, manic-depressive psychosis, major
    depressive disorder, schizophrenia, alcohol dependence, Parkinson’s syndrome, Alzheimer’s disease, amyotrophic lateral
    sclerosis, ulcerative colitis, gallstones, hepatitis B, duodenal ulcer, Crohn’s disease, glaucoma, age-related macular degeneration,
    pathological myopia, chronic bronchitis, chronic obstructive pulmonary disease, asthma.	 	Oral
    swab/blood	 	10
    days	 	1750	 	350	 	130	 	240

 

    	Address: Biopharmaceutical Park, Technology Innovation Six Street, Economic and Technological Development Zone of Yizhuang, Beijing Tel: 010-56315456

    	
 ThorGene (Beijing) Medical Technology Co., Ltd.

    

 

	 	 	Comprehensive
    Genetic Testing	 	1800+

    60
    high-risk genetic diseases; common high-incidence tumors (male 21 /female 25 ); 40+ common non-tumor diseases; 70+ drug genes; 1600+
    genetic diseases carrying; 50+ personal traits.
	 	Comprehensive
    genetic testing covers common diseases, genetic diseases, drug genes, personal traits, etc, which can help provide guidance and suggestions
    for healthy living and daily physical examinations, and makes disease prevention more accurate by scientific analysis.	 	Saliva
    collector/blood	 	 

    8
    days

     
	 	5880	 	1176	 	235	 	400
	 	 	Whole-exome
    Sequence Genetic Testing	 	Whole-exome
                                            sequence genetic testing covers about 1% of the human genome, about 50 million sites.

     
	 	Whole-exome
                                            sequence genetic testing covers common diseases, genetic diseases, safe medication use,
                                            nutrition metabolism, personal traits, etc, which can help provide guidance and suggestions
                                            for healthy living and daily physical examinations, and makes disease prevention more accurate
                                            by scientific analysis.

     
	 	Saliva
    collector/blood	 	 

    25-30
    days

     
	 	26800	 	5360	 	330	 	500
	 	 	Whole-genome
    Sequence Genetic Testing	 	 

    Whole-genome
    sequence genetic testing covers all genetic information about the human body, about 3 billion sites, and provides health management
    advice.

     
	 	Whole-genome
                                            sequence genetic testing covers common diseases, genetic diseases, safe medication use,
                                            nutrition metabolism, personal traits, etc, which can one-to-one appointment interpretation
                                            service and help provide guidance and suggestions for healthy living and daily physical examinations,
                                            and makes disease prevention more accurate by scientifically analyzing using genetic data
                                            and physical examination data.

     
	 	Saliva
    collector/blood	 	25-30
    days	 	49800	 	9960
    	 	330	 	500
	 	 	Specimen
    requirements	 	Saliva: Use a saliva collector to collect saliva and send it to the testing laboratory within 72 hours at normal temperature.

                                                                                 

	 	 	 	Oral mucosal cells: Requires 1 2 oral swabs, preserved and transported at normal temperature

                                                                                 

	 	 	 	Blood: Use an EDTA anticoagulant tube (purple cap tube) to take blood no less than 2ml, and then invert it for 2-3 times, but avoid violent shaking.

                                                                                 

	 	 	 	Delivery requirements: At least 5 samples of a single test product can be mailed. We charge certain packaging fees and express fees for individual users.

                                                                                 

	 	 	Notes	 	Report
printing: The complete report is bound and printed by a professional graphic organization entrusted by our company, and the printing
and express delivery costs are borne by the medical examination organization (except for the whole-exome sequence genetic testing and
the whole-genome sequence genetic testing). If you choose the simplified version of the report, the medical examination institution will
print it out. 

 

Material
expenses and express fee of genetic testing products ( Yuan / set)

 

	Fees	 	Items	 	Price
	

    
	 	Sampling
    package	 	6
	Material
fee	 	Oral
    swab sampling kit	 	15
	 	 	Saliva
    sampling kit	 	30
	Express
    fee	 	Mailing
    sampling kits to users	 	15

 

4.2
Time Limit of Genetic Testing

 

Refer
to testing cycle in the list of genetic health service products. Party A may inquire and download reports in specific channel appointed
by Party B.

 

4.3
Payment

 

A.
Party B shall summarize sequencing services completed in previous month on the first working day of each month (once a month), and provide
lists of sequencing services and receivables to Party A;

 

B.
Party A shall give payment in full for sequencing services in previous period at agreed price before the 10th day of each month. In the
meantime, Party B shall issue VAT invoice to Party A; plain VAT invoice special VAT invoice

 

electronic
plain VAT invoice

 

    	Address: Biopharmaceutical Park, Technology Innovation Six Street, Economic and Technological Development Zone of Yizhuang, Beijing Tel: 010-56315456

    	
 ThorGene (Beijing) Medical Technology Co., Ltd.

    

 

Party
A’s Deposit Bank, Payment Information and Account:

 

Account
Name: Tianjin Beroni Biotechnology Co., Ltd.

 

Deposit
Bank: Agricultural Bank of China-Tianjin Jinxi Branch

 

Account
Number: 02 0202 0104 0016 735

 

Tax
Registration Number: 91120 111 300 392 5013

 

Address
and Tel: 302, Building10, Zhonglian Industrial Park, Xiqing Automobile Industrial Zone, Tianjin, China, 022-58530396

 

C.
If Party A pays by check, Party A shall fill in check information completely, or it shall bear all economic losses caused to Party B
thereby.

 

Party
B’s Deposit Bank and Account:

 

Account
Name: ThorGene (Beijing) Medical Technology Co., Ltd.

 

Deposit
Bank: Agricultural Bank of China-Beijing Jinghai Road Branch

 

Account
Number: 1122 1201 0400 0277 3

 

V.
Agreement Modification, Termination and Default Responsibility

 

5.1
Within validity of Agreement, two parties may modify and supplement clauses. Any amendments and supplements shall be confirmed in written.

 

5.2
Any party who intends to terminate the Agreement early shall notice the other party in written 30 days in advance.

 

VI.
Confidentiality Obligations

 

6.1
Party B shall keep materials and users’ personal information provided by Party A confidential and shall not directly or indirectly
disclose such information to any third party without written approval of Party A. The aforesaid business materials and information include
Party A and Party B’s business plans, strategies, arrangements and relevant documents, as well as Party B’s intellectual
achievements such as strategies, creative ideas, media scheduling made and proposed for Party A. Both parties shall only disclose such
commercial data or information to personnel directly related to performance of Agreement, and shall inform relevant personnel of the
confidentiality.

 

    	Address: Biopharmaceutical Park, Technology Innovation Six Street, Economic and Technological Development Zone of Yizhuang, Beijing Tel: 010-56315456

    	
 ThorGene (Beijing) Medical Technology Co., Ltd.

    

 

VII.
Dispute Settlement

 

Any
disputes arising during execution of the Agreement shall be settled by both parties through friendly negotiation. If no settlement can
be reached after negotiation, the dispute shall be submitted to people’s court of the place where Party A is operated.

 

VIII.
General Provisions

 

8.1
The Agreement is prepared in quadruplication, each party holding two with the same legal effect.

 

8.2
This Agreement is valid for 2 years, from August 11, 2020 to August 10, 2022. The Agreement may be automatically
extended for years if neither party requests to terminate within 30 days after expiring date.

 

8.3
Termination of Agreement shall not be end of Party B’s services which shall be subject to expiry date of services provided by Party
A.

 

8.4
Matters not covered herein shall be settled through negotiation between the two parties. Any amendments and supplements shall be confirmed
by a supplementary agreement signed and sealed by both parties. Supplementary agreement shall be attached as annex and have the same
legal effect as this Agreement.

 

8.5
Any clauses that are identified as invalid, illegal or unenforceable are useless, but shall not affect the validity, legality or enforceability
of other provisions.

 

	 	 

 

	Party
    A: (Seal)	Party
    B: (Seal)
	 	 
	Legal
    or Authorized Person (Signature):	Legal
    or Authorized Person (Signature):
	 	 
	Date:	Date:

 

    	Address: Biopharmaceutical Park, Technology Innovation Six Street, Economic and Technological Development Zone of Yizhuang, Beijing Tel: 010-56315456

    	
 ThorGene (Beijing) Medical Technology Co., Ltd.

    

 

Annex
1:

General
Process for Genetic Product Services

 

Specimen
Collection Requirements

 

I.
Oral Swab Sampling

 

1.
Use one sampling swab to scrape inner wall of left oral cavity 30 times, snap swab and keep it in sampling tube.

 

2.
Use another sampling swab to scrape inner wall of right oral cavity 30 times, snap swab and keep it in sampling tube.

 

3.
Clear mouth 30 minutes before sampling and do not eat, smoke, drink or chew gun after sampling.

 

II.
Saliva Sampling

 

1.
Spit saliva gently into funnel until saliva (not bubble) reaches the height of filling line, hold sampling tube in upright position,
and turn funnel counterclockwise with the other hand.

 

2.
Keep sampling tube upright, remove cover from bottom of the tube and tighten sampling tube with the cover. Then shake the tube 5 times
until saliva is fully mixed with preservation solution, and put it into plastic package for sampling tube.

 

3.
Saliva specimen shall be free of debris and sputum.

 

III.
Blood Sampling

 

1.
Apply EDTA anticoagulation tube (purple-cap tube) to sample at least 2ml blood (not less than 4ml for combined genetic risks test). For
early screening of S9 colorectal cancer, users should apply ctDna tube only to sample at least 10ml blood. Then turn the tube up and
down for 2-3 times after sampling but avoid violent shock.

 

2.
Label collection tube with bar code which should be in straight position for easy scanning.

 

3.
Put collection tube in sampling bag, seal and recheck the bar code.

 

4.
Genetic Testing Registration Form (with the same label and specimen information as collection tube)

 

    	Address: Biopharmaceutical Park, Technology Innovation Six Street, Economic and Technological Development Zone of Yizhuang, Beijing Tel: 010-56315456

    	
 ThorGene (Beijing) Medical Technology Co., Ltd.

    

 

Preservation
Conditions of Blood Specimen

 

Refrigeration
(not frozen ) at 4 ° C for 3-5 days.

 

Delivery
Requirement

 

To
ensure good delivery, Party A shall choose S.F. or Jingdong Express to transmit specimens which shall be transported through cold chain
with ice bags and foam boxes to laboratory in 3-5 days’ carriage. The transportation temperature shall be 2-8°C. S9 products
shall be stored at 18-30°C and transported to laboratory within 72h.

 

Overview
of Specimen Information

 

1.
Oral swab / saliva specimens that need to be tested.

zhudandan@thorgene.com,wangcong@thorgene.com,congyao@thorgene.com.

2.
Genetic Testing Registration Form (with the same label and specimen information as collection tube). Principal to mail specimens shall
fill in list of specimen information and send it to mailbox: zhudandan@thorgene.com, wangcong@thorgene.com,congyao@thorgene.com.

 

List
of specimen information:

 

	 	 	Subject
    Info (not null)	 	 	 	 	 	 	 	 	 	Delivery
    Address for Report (optional)
	Test
    Item (not null)	 	Name	 	Gender	 	Age	 	Tel	 	Submission

                                                                                Unit

                                                                                (not
                                            null)
	 	Submission

                                                                                Date

                                                                                (not
                                            null)
	 	Employer
                                            of Subject

                                                                                (showed
                                            in report)
	 	Customer
                                            No.

                                                                                (optional)
	 	Recipient
    	 	Tel	 	Address
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

4.
The list of specimen information must be sent to corresponding address together with specimens.

 

Specimen
Mailing

 

1.
Sepcimen reception: Specimens from Beijing shall be mailed to Beijing laboratory, the others shall be sent to Nanjing laboratory.

 

Note:
Products of Endocrine System Drug Genetic Testing, Gene Testing for Usage of Anti-hypertension Drugs, Comprehensive Genetic Testing,
Whole-exome Sequence Genetic Testing, Whole-genome Sequence Genetic Testing, HPV Gene Testing, Gene Testing of Safe Medication for Children,
All-type Adult Drug Gene Testing shall be sent to Beijing.

 

    	Address: Biopharmaceutical Park, Technology Innovation Six Street, Economic and Technological Development Zone of Yizhuang, Beijing Tel: 010-56315456

    	
 ThorGene (Beijing) Medical Technology Co., Ltd.

    

 

2.
Submission address:

 

Nanjing:
2F, Building A, Yangzi Technological Innovation Centre, Pubin Road, Pukou District, Nanjing. Cong Wang (18914472085)

 

Beijing:
A1-2F, Biopharmaceutical Park, No. 88, Technology Innovation Six Street, Economic and Technological Development Zone, Beijing. Dan Zhu
(010-56315456 )

 

3.
Mailing:

 

Principals
pack and mail specimens by Jingdong or S.F. Express (land transportation).

 

1
Jingdong Express

 

Scan
company’s mail QR code of JD express — enter WeChat mini-program to place an order — fill in mail information (indicate
company name “ThorGene (Beijing) Medical Technology Co., Ltd.”) — mail it to the company and choose “monthly
statement”. (contact customer service staff for QR code)

 

If
you are not convenient to place an order directly, please contact business leader or customer service staff of ThorGene to place orders
for you.

 

2
S.F. Express

 

Self-service
ordering: indicate company name of “ThorGene (Beijing) Medical Technology Co., Ltd.” for courier to verify our information,
and cooperate courier to check specimens. If courier needs to inquire company’s qualification, you can provide name of our company.

 

If
there is any problem in receiving goods, you can contact business person in charge for negotiation.

 

Approach
to Specimen Collection Failure

 

Party
B shall inform Party A of information of the subject whose specimen is not qualified. Party A shall contact the person for a second free
sampling and Party B shall carry out another testing and bear relevant transportation expenses; or both parties may negotiate to terminate
the test.

 

Report
Acquisition

 

Log
in “Channel Home” in Party B’s system to inquire and download reports.

 

Report
Interpretation

 

For
general genetic testing items provided by ThorGene, the test reports will offer detailed interpretation and health management advice.
If you have any questions, please call ThorGene hotline for consultation: 400-8088-978.

 

    	Address: Biopharmaceutical Park, Technology Innovation Six Street, Economic and Technological Development Zone of Yizhuang, Beijing Tel: 010-56315456

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]